The Marseille Cancer Research Center celebrates its 50th anniversary ! -


The objectives of the laboratory are to identify and characterize the pathways altered during oncogenesis in breast cancers, visceral cancers and prostate cancer.
Results are then discussed between researchers and clinicians, as means to improve classification, prognosis, therapeutic efficicency and/or therapeutic options.

This challenge is addressed through 3 axes :

      Circulating Tumor Cells & Metastases
    Genomics of Solid Tumors
    Nanoparticles & Therapeutic Targeting
    Antibody-Drug Conjugate (ADC)

Our project is to develop tools able to predict drug efficiency in real time, for each patient.

This is achieved by addressing 2 challenges:

  • Establishing the role of Circulating Tumor cells (CTCs) as a - not very invasive - biomarker for therapy efficiency and more specifically to detect early signs of drug resistance mechanisms development,
  • Developing “complex tumor units”, the next generation of patient-derived tumor organoids or tumoroids. They are 3D tumor units composed of malignant cells interacting with their microenvironment (particularly with fibroblasts, which represent the major cell population within the tumor microenvironment or stroma, endothelial and/or immune cells).

These two approaches, combined with microfluidic technology, will lay the basis for a “metastasis-on-a-chip” device. This fully humanized and personalized "tumor on a chip" model, will help us in the understanding and the targeting of the steps involved during metastases occurrence.


Breast cancer (BC), as most cancers, is a heterogeneous disease that can be classified according to histoclinical features and to molecular biology. Our goal is to progress in the molecular and cellular definition of aggressive cancers, especially breast tumors, and help improve their treatment. For this, in collaboration with clinicians, we initiated a personalized medicine program enrolling metastatic patients. The program comprises: metastasis biopsy, banking, extraction of nucleic acids, NGS, grafting to obtain Patient-derived xenograft (PDX), establishment of the molecular identity of a metastasis and its drug response. Therapies are selected upon two types of results: genomics studies and model-based. We established a bank of well-characterized primary and metastatic tumors (mostly from breast metastases so far). These xenografts conserve the genome and gene expression of their cognate tumors and are therefore excellent models for functional studies and drug testing. We are now involved in the next generation ex vivo modeling of tumors, using patient-derived tumoroids.

Nanoparticles & Therapeutic Targeting Palma Rocchi group
Antibody-Drug Conjugate (ADC)

ADCs are a rapidly evolving therapeutic class and many efforts are done to improve efficacy and safety. Design of an effective ADC for cancer therapy requires the identification of an appropriate target, a monoclonal antibody against the target, potent cytotoxic agents, and the conjugation of the monoclonal antibody to one of these agents.We identified nectin-4 as a potential therapeutic target in breast cancer. Nectin-4 (encoded by the PVRL4 gene) is a cell adhesion molecule involved in the formation and maintenance of adherens junctions. Nectin-4 is expressed during foetal development, but is re-expressed as a tumor-associated antigen with pro-oncogenic properties in various carcinomas. In breast cancer, we have shown the correlation of nectin-4 expression with basal biomarkers, Triple-negative (TN) status and HER2 expression. Recently, we showed that nectin-4 is both a new prognostic biomarker and a therapeutic target for ADC in patients with TN breast cancer. We thus developed an ADC (N41mab-vcMMAE) comprising a human anti-nectin-4 monoclonal antibody conjugated to the toxin monomethyl auristatin-E (MMAE). In vitro, this ADC bound to nectin-4 with high affinity and specificity and induced its internalization as well as dose-dependent cytotoxicity on nectin-4-expressing breast cancer cell lines. In vivo, it induced rapid, complete and long-lasting responses of xenografted nectin-4-positive TN BC samples including primary tumors, local relapses, and metastatic lesions; efficiency was dependent on both the dose and the nectin-4 expression level. Clinical development is currently under process. We plan to evaluate the targeting of nectin-4 in treatment-resistant HER2-positive breast cancer and in other carcinomas like lung cancer.

the Team publications
Mar 2022 Cancers

CSPG4 Expression in GIST Is Associated with Better Prognosis and Strong Cytotoxic Immune Response.

de Nonneville A, Finetti P, Picard M, Monneur A, Pantaleo MA, Astolfi A, Ostrowski J, Birnbaum D, Mamessier E, Bertucci F

Feb 2022 Cancers

Identification of Atypical Circulating Tumor Cells with Prognostic Value in Metastatic Breast Cancer Patients.

Lopresti A, Acquaviva C, Boudin L, Finetti P, Garnier S, Aulas A, Liberatoscioli ML, Cabaud O, Guille A, de Nonneville A, Da Costa Q, Denicolai E, Pakradouni J, Goncalves A, Birnbaum D, Bertucci F, Mamessier E

Feb 2022 Journal of the National Cancer Institute

RE: NDRG1 in Aggressive Breast Cancer Progression and Brain Metastasis.

de Nonneville A, Finetti P, Mamessier E, Bertucci F

Jan 2022 Journal for immunotherapy of cancer

Immunologic constant of rejection signature is prognostic in soft-tissue sarcoma and refines the CINSARC signature.

Bertucci F, Niziers V, de Nonneville A, Finetti P, Mescam L, Mir O, Italiano A, Le Cesne A, Blay JY, Ceccarelli M, Bedognetti D, Birnbaum D, Mamessier E

Jul 2021 Advanced science

Dependency and Pejorative Prognostic Value in Triple-Negative Breast Cancer.

de Nonneville A, Finetti P, Birnbaum D, Mamessier E, Bertucci F

May 2021 Nature communications

Targeting Treg cells with GITR activation alleviates resistance to immunotherapy in murine glioblastomas.

Amoozgar Z, Kloepper J, Ren J, Tay RE, Kazer SW, Kiner E, Krishnan S, PosadaJM, Ghosh M, Mamessier E, Wong C, Ferraro GB, Batista A, Wang N, Badeaux M,Roberge S, Xu L, Huang P, Shalek AK, Fukumura D, Kim HJ, Jain RK

May 2021 Oncoimmunology

Immune landscape of inflammatory breast cancer suggests vulnerability to immune checkpoint inhibitors.

Bertucci F, Boudin L, Finetti P, Van Berckelaer C, Van Dam P, Dirix L, ViensP, Gonçalves A, Ueno NT, Van Laere S, Birnbaum D, Mamessier E

May 2021 Genome medicine

Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial.

Bertucci F, Gonçalves A, Guille A, Adelaïde J, Garnier S, Carbuccia N, BillonE, Finetti P, Sfumato P, Monneur A, Pécheux C, Khran M, Brunelle S, Mescam L,Thomassin-Piana J, Poizat F, Charafe-Jauffret E, Turrini O, Lambaudie E,Provansal M, Extra JM, Madroszyk A, Gilabert M, Sabatier R, Vicier C, MamessierE, Chabannon C, Pakradouni J, Viens P, André F, Gravis G, Popovici C, BirnbaumD, Chaffanet M

Feb 2018 Annals of translational medicine

CMTM6 stabilizes PD-L1 expression and refines its prognostic value in tumors.

Mamessier E, Birnbaum DJ, Finetti P, Birnbaum D, Bertucci F

May 2021 NPJ breast cancer

The CINSARC signature predicts the clinical outcome in patients with Luminal B breast cancer.

Goncalves A, Finetti P, Birnbaum D, Bertucci F

Mar 2020 Molecular oncology

NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non-inflammatory breast cancers.

Bertucci F, Rypens C, Finetti P, Guille A, Adélaïde J, Monneur A, Carbuccia N, Garnier S, Dirix P, Gonçalves A, Vermeulen P, Debeb BG, Wang X, Dirix L, Ueno NT, Viens P, Cristofanilli M, Chaffanet M, Birnbaum D, Van Laere S

Aug 2019 Cancers

A Tyrosine Kinase Expression Signature Predicts the Post-Operative Clinical Outcome in Triple Negative Breast Cancers.

de Nonneville A, Finetti P, Adelaide J, Lambaudie É, Viens P, Gonçalves A, Birnbaum D, Mamessier E, Bertucci F

Jun 2019 JCI insight

Sensitive and easy screening for circulating tumor cells by flow cytometry.

Lopresti A, Malergue F, Bertucci F, Liberatoscioli ML, Garnier S, DaCosta Q, Finetti P, Gilabert M, Raoul JL, Birnbaum D, Acquaviva C, Mamessier E

Apr 2018 Biochimica et biophysica acta. Reviews on cancer

Molecular classification as prognostic factor and guide for treatment decision of pancreatic cancer.

Birnbaum DJ, Bertucci F, Finetti P, Birnbaum D, Mamessier E

Apr 2020 Hepatology (Baltimore, Md.)

Dual Programmed Death Receptor-1 and Vascular Endothelial Growth Factor Receptor-2 Blockade Promotes Vascular Normalization and Enhances Antitumor Immune Responses in Hepatocellular Carcinoma.

Shigeta K, Datta M, Hato T, Kitahara S, Chen IX, Matsui A, Kikuchi H, Mamessier E, Aoki S, Ramjiawan RR, Ochiai H, Bardeesy N, Huang P, Cobbold M, Zhu AX, Jain RK, Duda DG

Jun 2019 Cancers

Liquid Biopsies for Ovarian Carcinoma: How Blood Tests May Improve the Clinical Management of a Deadly Disease.

Mari R, Mamessier E, Lambaudie E, Provansal M, Birnbaum D, Bertucci F, Sabatier R

Mar 2022 The EMBO journal

Ketogenic HMG-CoA lyase and its product β-hydroxybutyrate promote pancreatic cancer progression.

Gouirand V, Gicquel T, Lien EC, Jaune-Pons E, Da Costa Q, Finetti P, Metay E, Duluc C, Mayers JR, Audebert S, Camoin L, Borge L, Rubis M, Leca J, Nigri J, Bertucci F, Dusetti N, Lucio Iovanna J, Tomasini R, Bidaut G, Guillaumond F, Vander Heiden MG, Vasseur S